Cancer Research UK logo.
SearchDonate
  • Search

A trial of idasanutlin with abiraterone or enzalutamide for prostate cancer that has spread (MAdCaP)

Overview

Cancer types:

Prostate cancer, Secondary cancers

Status:

Results

Phase:

Phase 1

Details

This trial looked at idasanutlin for prostate cancer that was no longer responding to hormone therapy and had spread to another part of the body.

The trial was supported by Cancer Research UK. People could join between 2014 and 2017. The team presented the results at a conference in 2018.

Idasanutlin is pronounced eye-dah-san-ut-lin.

Recruitment start: 31 March 2014

Recruitment end: 3 July 2017

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Rob Jones

Supported by

Cancer Research UK

NHS Greater Glasgow and Clyde

NIHR Clinical Research Network: Cancer

Roche

University of Glasgow

Other information

This is Cancer Research UK trial number CRUKE/12/032.

Last reviewed: 24 Feb 2026

CRUK internal database number: 10085

Help and support